Recent studies suggest that IL-6 and TNF-α inhibitor drugs such as tocilizumab may be a potential therapeutic option to ameliorate the negative outcomes of severe COVID-19 patients.9 Clinical trials are needed to determine optimal patient selection and timing for the use of tocilizumab. Here, IL6 is linked to COVID-19.